Don't miss your chance to leverage Kalorama Information's expert insights. Equip your business with the knowledge to anticipate changes, optimize product development, and maximize your strategies in the dynamic IVD landscape.
Ready to take action? Purchase the "IVD Test Procedure Volumes, 2024-2029" report today and secure your competitive advantage in this billion-dollar industry.
Kalorama Information's "IVD Test Procedure Volumes, 2024-2029" report provides a deep dive into the global trends shaping in vitro diagnostic (IVD) procedural volumes. Designed to complement Kalorama's comprehensive market analysis in The Worldwide Market for In Vitro Diagnostic (IVD) Tests, 17th Edition, this essential report delivers actionable data on the growth, challenges, and emerging opportunities in the IVD space.
As a rapidly evolving market, the IVD landscape in 2024 is set to thrive, driven by new technologies, evolving healthcare spending, and a surge in demand for precision diagnostics. Our report not only identifies the most significant procedural segments but also breaks down the impact of ongoing innovations.
With this detailed market research, you can stay ahead of industry developments and make informed business decisions. Whether you are looking to expand your product portfolio, explore new market segments, or refine your strategic approach, "IVD Test Procedure Volumes, 2024-2029" offers the data and insights you need to succeed.
Why Choose This Report?
Comprehensive Market Data
Gain an in-depth understanding of IVD procedural volumes by type, region, and country. From self-testing and professional point-of-care (POC) to clinical chemistry, hematology, and beyond-this report covers it all.
Unmatched Insights into Growth Opportunities
Identify high-growth segments by exploring emerging markets and the potential of precision medicine applications.
Forward-Looking Analysis
Understand the trends impacting the IVD market, including shifts in regulatory landscapes, new product developments, and changing disease profiles. This report provides a comprehensive forecast from 2024 to 2029.
Strategic Guidance for Industry Players
Discover how market dynamics, healthcare system trends, and cost pressures are shaping the future of IVD. Use these insights to develop strategies for product positioning, market entry, and growth.
Scope & Methodology
The report includes:
Global IVD Procedure Volumes by type, covering self and professional POC, clinical chemistry, immunoassay, molecular diagnostics, hematology, coagulation, microbiology, blood banking, and histology/cytology.
Regional and Country-Specific Data for IVD procedures and their projected growth rates.
Cost Analysis of various IVD tests to evaluate profitability and potential revenue streams.
Table of Contents
Chapter One: Executive Summary
IVD Procedure Volume Estimate and Forecast
Figure 1-1: Global IVD Procedure Volumes, 2024 and 2029 (in millions # volume)
Scope & Methodology
About Kalorama Information
Chapter Two: Introduction
Overview
Industry Trends
Table 2-1: Global IVD Procedural Volume & Product Sales (includes glucose tests), 2024-2029 (in millions # volume; $ million)
Figure 2-1: Global IVD Procedural Volume & Product Sales (includes glucose tests), 2024-2029 (in millions # volume; $ million)
COVID-19
Demographic Trends
Global Population and Aging
Figure 2-2: Global Fertility Rate vs. Population Size, 1950-2050 (billion)
Figure 2-3: Global Population Distribution, 2022
Table 2-2: Elderly Support Ratio in Various Countries, 2010 and 2050 (Australia; Brazil; Canada; China; China, Hong Kong SAR; France; Germany; India; Italy; Japan; Mexico; Saudi Arabia; Singapore; South Africa; Spain; Turkey; United Kingdom; United States; World)
Workforce Reduction
Table 2-3: Age Under 15 and Over 65, by Continent, 2020 (Africa, Asia, Europe, Latin America/Caribbean, North America, Oceania)
Increase in Chronic Diseases
Figure 2-4: Leading Causes of Death Globally, by Number of Deaths, 2021 (in millions)
Middle East Respiratory Syndrome-Coronavirus (MERS-CoV)
Marburg
SARS-CoV-2 (COVID-19)
Monkeypox
Table 2-5: Selected FDA EUAs for Molecular Diagnostic Tests for Monkeypox
Emerging and Emerged Markets
Table 2-6: Market Potential, by Total Population and Percent Urban, 2023 (population in million) (Brazil; Canada; Chile; China; Colombia; Egypt; India; Malaysia; Mexico; Peru; Poland; Russia; South Africa; South Korea; Saudi Arabia; Turkey; Ukraine; United States; Vietnam)
Chapter Three: IVD Testing Segments
IVD Testing Trends
Table 3-1: IVD Procedural Volume including Blood Glucose Tests, by Item, 2024-2029 (millions) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
Figure 3-1: IVD Procedural Volume including Blood Glucose Tests, by Item, 2024 (millions) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
Figure 3-2: IVD Procedural Volume including Blood Glucose Tests, by Item, 2029 (millions) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
Table 3-2: IVD Procedural Volume including Blood Glucose Tests, Share by Item, 2024-2029 (%) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
Figure 3-3: IVD Procedural Volume including Blood Glucose Tests, Share by Item, 2024 (%) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
Figure 3-4: IVD Procedural Volume including Blood Glucose Tests, Share by Item, 2029 (%) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
Table 3-18: IVD Product Sales excluding Blood Glucose Tests, Share by Item, 2024-2029 (%) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
Figure 3-25: IVD Product Sales excluding Blood Glucose Tests, Share by Item, 2024 (%) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
Figure 3-26: IVD Product Sales excluding Blood Glucose Tests, Share by Item, 2029 (%) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
Chapter Four: Global IVD Markets
General
Table 4-1: IVD Procedural Volume including Blood Glucose Tests, by Region, 2024-2029 (millions) (Africa; Asia/Pacific [China, Japan, Other Countries & Territories]; Eastern Europe; Mexico, Central, & South America; Middle East; North America [United States; Canada]; Western Europe)
Figure 4-1: IVD Procedural Volume including Blood Glucose Tests, by Region, 2024-2029 (millions) (Africa; Asia/Pacific; Eastern Europe; Mexico, Central & South America; Middle East; North America; Western Europe)
Table 4-2: IVD Procedural Volume including Blood Glucose Tests, Share by Region, 2024-2029 (%) (Africa; Asia/Pacific [China, Japan, Other Countries & Territories]; Eastern Europe; Mexico, Central & South America; Middle East; North America [United States; Canada]; Western Europe)
Figure 4-2: IVD Procedural Volume including Blood Glucose Tests, Share by Region, 2024 (%) (Africa; Asia/Pacific; Eastern Europe; Mexico, Central & South America; Middle East; North America; Western Europe)
North America
Table 4-3: North America IVD Procedural Volume including Blood Glucose Tests and Market Share, 2024-2029 (millions) (%) (Canada, United States)
Figure 4-3: North America IVD Procedural Volume including Blood Glucose Tests, 2024-2029 (millions) (Canada, United States)
United States
Canada
Mexico, Central & South America
Table 4-4: Mexico, Central & South America IVD Procedural Volume including Blood Glucose Tests and Market Share, 2024-2029 (millions)
Figure 4-4: Mexico, Central & South America IVD Procedural Volume including Blood Glucose Tests, 2024-2029 (millions)
Brazil
Mexico
Other Central & South America
Argentina
Chile
Colombia
Peru
Venezuela
All Other Countries & Territories
Western Europe
Table 4-5: Western Europe IVD Procedural Volume including Blood Glucose Tests and Market Share, 2024-2029 (millions) (%)
Figure 4-5: Western Europe IVD Procedural Volume including Blood Glucose Tests, 2024-2029 (millions)
France
Germany
Italy
Spain
United Kingdom
Other Western Europe
Austria
Belgium
Denmark
Finland
Greece
Ireland
Norway
Netherlands
Portugal
Sweden
Switzerland
All Other Countries & Territories
Eastern Europe
Table 4-6: Eastern Europe IVD Procedural Volume including Blood Glucose Tests and Market Share, 2024-2029 (millions) (%)
Figure 4-6: Eastern Europe IVD Procedural Volume including Blood Glucose Tests, 2024-2029 (millions)
Russia
Other Eastern Europe
Czech Republic
Hungary
Poland
Romania
Ukraine
All Other Countries
Asia/Pacific
Table 4-7: Asia/Pacific IVD Procedural Volume including Blood Glucose Tests and Market Share, 2024-2029 (millions) (%) (China, Japan, Other Countries & Territories)
Table 13-1: Histology/Cytology Procedural Volume, by Type, 2024-2029 (CTCs; Flow Cytometry; Immunohistochemistry; In situ Hybridization; Pap Tests; Traditional non-Pap Stains)
Figure 13-1: Regional Histology/Cytology Procedure Volumes, 2024 (Asia Pacific, Europe, North America, Rest of World)
Types of Tests
Immunohistochemistry Tests
In Situ Hybridization Tests
Pap Tests
Traditional Non-Pap Stains
Circulating Tumor Cells
Flow Cytometry
Histology/Cytology IVD Product Sales
Table 13-2: Histology/Cytology Product Sales, by Type, 2024-2029 ($ million) (CTCs; Flow Cytometry; Immunohistochemistry; In situ Hybridization; Pap Tests; Traditional non-Pap Stains)
Pricing Trends
Table 13-3: Histology/Cytology $ Product Sales Per Procedure, by Type, 2024-2029